• Series A drives the expansion of Quibim’s product pipeline and foundational AI models and accelerates global commercial growth.
  • Asabys and Buenavista lead the round, joined UI Investissements, Go Hub and insiders; Amadeus Capital Partners, APEX Ventures, Partech, Adara, Leadwind and individual investors.

Valencia (Spain), and New York (USA), January 27, 2025 – Quibim, a leading healthtech company pioneering the use of imaging biomarkers for precision medicine, announced today the close of its $50 million Series A financing. The company has experienced remarkable growth in the number of patients analyzed by its products over the past year, driven by the regulatory approval of its solutions at the end of 2023. Patient analysis surged by 168% quarter-on-quarter. The financing was led by Asabys (through its fund Sabadell Asabys II) and Buenavista Equity Partners (through the BHG I fund, created in partnership with Columbus Venture Partners), and joined by  UI Investissements, and Go Hub as new investors. It was also joined by current investors, Amadeus Capital Partners, APEX Ventures, Partech, Adara and Leadwind, KFund’s early growth fund and individual investors, including Tony Fadell, Build Collective Principal, Nest founder and inventor of the iPod and Dr. Jonathan Milner, Founder of Abcam plc.  

Quibim is working towards the ambitious goal of understanding what is happening at every single tissue point in the human body, anytime, and non-invasively. To achieve this, the company develops foundational AI models applied to imaging that extract actionable insights from MRI, CT, and PET scans. These insights allow to characterize the phenotype and predict outcomes with precision in areas such as oncology, immunology and metabolic disorders. This is the pathway toward achieving human digital twins, dynamic models that not only reflect and allow to monitor health but also enhance patient stratification, improve the success rates of drug development programs, and enable treatment testing before application. Today, the company is building digital twins at the organ and lesion level, exemplified by solutions like QP-Brain, QP-Prostate, and QP-Liver. However, as the volume of whole-body scans and related imaging data continues to grow, in the coming years Quibim models will analyze the entire body. The vision of the company is to catalyze this revolutionary step in healthcare by merging imaging technologies, computing, and AI.

With over 170 installations worldwide, including prestigious institutions like Mass General Brigham and Stanford, and regulatory clearances across the US, EU, UK, and other regions, Quibim’s technology bridges the gap between research, clinical practice, and drug development. Last year, Philips announced a global partnership with Quibim to integrate its AI models into MR scanners, while the company also secured strategic alliances with leading biopharma giants such as Merck KGaA and Novartis.

“Quibim’s mission is to turn imaging into a catalyst for precision health, and we are deeply grateful to both our new and current investors for their support,” said Dr. Ángel Alberich-Bayarri, CEO and co-founder of Quibim. “Our global expansion into the U.S. is a critical milestone as we work with pharmaceutical leaders and healthcare providers to unlocking the power of imaging to revolutionize diagnostics and improve patient outcomes.”

Quibim’s product portfolio includes:

  • QP-Prostate®: the company’s flagship product is designed to enhance prostate cancer detection through an industry-leading AI-powered lesion detection*. CE, UKCA marked and 510(k) cleared.
  • QP-Brain®: AI-based early-stage neurological disease quantification software for quantification of early brain atrophy and lesions. CE, UKCA marked and 510(k) cleared. 
  • QP-Liver®: automated AI tool for MR diagnosis of diffuse liver diseases through accurate quantification of tissue fat and iron levels. CE and UKCA marked. 
  • QP-Insights®: A platform to manage, store and analyze multi-omics data in clinical trials and real-world data studies. QP-Insights is being used by global biopharmaceutical companies, academic medical centers and research consortiums, including the European Cancer Imaging Initiative to support Europe’s Beating Cancer Plan. QP-Insights is the platform managing the largest imaging datasets in the world, accounting for more than 100 million medical images.

Building on its success in Europe, Quibim plans to establish a strong U.S. presence through strategic collaborations with hospitals and pharmaceutical companies. By implementing its strategic plan and, through its suite of solutions already cleared by FDA, the company will support healthcare providers and clinical researchers to process an unprecedented amount of data from medical scans. Additionally, Quibim’s AI-powered imaging solutions will empower pharmaceutical companies by enhancing clinical trials and accelerating drug development with precise, actionable insights derived from imaging biomarkers.

The Series A financing will propel Quibim’s global expansion, starting in the U.S. market, to deepen its partnerships with leading pharmaceutical companies while growing the probability of success of clinical trials with an improved patient stratification. The funding will also support the launch of new medical imaging-based products. The company aims to integrate its AI-powered tools more broadly into clinical workflows, accelerating the adoption of precision medicine.

“Asabys is thrilled to support Quibim in transforming the imaging diagnostics space,” said Guillem Masferrer, Partner at Asabys Partners. “Their ability to combine AI with imaging biomarker discovery addresses critical unmet needs in oncology, neurology, and beyond. We are confident that Quibim’s innovative solutions will have a profound impact on global healthcare.”

“Quibim’s technology exemplifies the next wave of precision medicine,” said José Mesa, Partner at Columbus and Buenavista`s representative on the Board. “Their impressive track record with global pharmaceutical partnerships, including partnerships with companies such as Merck KGaA and Philips, exemplify Quibim’s role in transforming imaging data into valuable predictions for clinical trials and treatment planning. We expect that as Quibim develops its pipeline of companion diagnostic tools, we will see tremendous momentum for its technology and products.”

About Quibim

Quibim is a healthtech company pioneering tools that unlock imaging data to improve patient outcomes. Quibim is at the forefront of imaging biomarkers research in life sciences, driving the development of advanced algorithms that transform imaging data into actionable predictions in oncology, immunology, and neurology. The company leverages the capabilities of MRI, CT, and PET imaging to create regulatory-cleared Medical Devices that are seamlessly integrated into the workflows of healthcare providers worldwide. More than 170 healthcare institutions, research centers, hospitals, and clinical facilities are using Quibim products globally. In addition, Quibim has partnerships with Merck KGaA to develop imaging biomarker models to predict responses of cancer patients to immunotherapy and inform decisions in its global drug development efforts and with Phillips to launch AI-based imaging and reporting solutions for MRI prostate exams. Quibim has offices in New York City, US, Cambridge, UK, Valencia, Madrid, and Barcelona, Spain. For more info, visit www.quibim.com.

* In the US: Lesion detection functionality is 510(k) pending, not available for sale within the United States.

Media: